Respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD) require long-term management to keep symptoms under control and improve daily breathing. Symbicort 160 Turbuhaler is a commonly prescribed inhaler used as part of maintenance therapy for people dealing with these chronic lung conditions.
What is Symbicort 160 Turbuhaler?
Symbicort 160 Turbuhaler is a dry powder inhaler that delivers a combination of two active ingredients: Budesonide (160 mcg) and Formoterol (4.5 mcg). These medicines work together to help reduce inflammation in the airways and keep them open for easier breathing.
The Turbuhaler device is breath-activated, meaning the medicine is released when the user inhales, making it convenient for regular daily use.
How Symbicort 160 Works
The effectiveness of Symbicort 160 comes from its dual mechanism of action:
- Budesonide is an inhaled corticosteroid that helps reduce swelling and irritation inside the airways.
- Formoterol is a long-acting bronchodilator that relaxes the airway muscles, allowing air to flow more freely.
Together, these components help maintain open airways and reduce respiratory symptoms over time.
Uses of Symbicort 160 Turbuhaler
Symbicort 160 Turbuhaler is mainly used for:
- Maintenance treatment of moderate to severe asthma
- Long-term symptom control in COPD patients
- Reducing episodes of breathlessness, wheezing, and chest tightness
- Supporting better lung function when used regularly
It is important to note that this inhaler is not intended for immediate relief during sudden asthma attacks.
Benefits of Regular Use
When used consistently as prescribed, Symbicort 160 Turbuhaler may help:
- Improve overall breathing comfort
- Maintain better daily control of respiratory symptoms
- Support long-term airway health
Regular use plays a key role in managing chronic respiratory conditions effectively.
How to Use Symbicort 160 Turbuhaler
- Use the inhaler exactly as advised by a healthcare professional
- Inhale deeply through the Turbuhaler to receive the correct dose
- Rinse the mouth after use to reduce throat irritation
- Do not exceed the recommended dosage
- Proper inhaler technique is essential for optimal results.
Possible Side Effects
Some users may experience mild side effects such as throat irritation, hoarseness, headache, or cough. In rare cases, palpitations or oral fungal infections may occur. Consulting a healthcare provider is recommended if side effects persist.
Conclusion
Symbicort 160 Turbuhaler plays an important role in the long-term management of asthma and COPD. With its combination of an anti-inflammatory agent and a long-acting bronchodilator, it helps maintain open airways and supports better breathing when used regularly as part of a prescribed treatment plan.
Asthma and COPD Drug Market report published by Value Market Research, which studies the future outlook of the market.
It includes the size, share, growth, trends, key players, segments and regional analysis in detail during the study year 2020-2027.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the asthma and copd drug market market include Mylan, Aerovance Inc. Alkermes Inc. Almirall SA.
Genentech Inc. Sepracor, Inc. Skyepharma plc.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Asthma and COPD Drug Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/asthma-and-copd-drug-market/download-sampleMarket DynamicsThe advancement in the medical sciences and technology and the heavy investment of the giant drug and pharmaceutical companies have been producing pioneer therapies and drugs for treating asthma and COPD since the late twentieth century.
High prevalence of asthma and COPD, generation of innovative medicines and their approval by the Food and Drug Administration (FDA), and massive patients of asthma and COPD receiving the treatment accelerate the growth of the drug markets.
